The global onychomycosis treatment market size reached US$ 3.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.37% during 2023-2028.
Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can lead to discomfort, chronic pain and disfigurement. Proximal subungual, white superficial and distal subungual are some of the types of onychomycosis. It is a common nail infection in patients with athlete’s foot and is caused by various organisms, such as dermatophytes, yeasts and non-dermatophyte molds. Onychomycosis is characterized by symptoms, including distortion in the shape of nails, foul smell, whitish to yellow-brown discoloration and brittle, ragged and crumbly texture of the nails. It is usually diagnosed through potassium, oxygen and hydrogen (KOH) examination, culture and histopathological examinations of nail clippings and nail biopsies and is treated through laser therapy, drugs and photodynamic therapies.
Onychomycosis Treatment Market Trends:
The increasing prevalence of chronic medical ailments, such as onychomycosis, human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is highly prone to circulatory disorders and weakened immune system, is providing a thrust to the market growth. Onychomycosis is also highly prevalent among millennials and adults due to the increased exposure to public swimming pools and utilization of tight, contaminated or soiled clothes, shoes and socks. Additionally, the development of water-soluble antifungal treatment solutions that can be administered orally is providing a thrust to the market growth. They aid in preventing secondary bacterial infections and prevent the growth of fungus. Other factors, including the widespread utilization of topical nail lacquers and ointments to maintain nail hygiene, along with the significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global onychomycosis treatmentmarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on disease type, treatment type, drug class and distribution channel.
Breakup by Disease Type:
Distal Subungual Onychomycosis
Proximal Subungual Onychomycosis
White Superficial Onychomycosis
Candidal Onychomycosis
Others
Breakup by Treatment Type:
Laser Therapy
Photodynamic Therapy
Drug Treatment
Breakup by Drug Class:
Allylamine
Azole
Griseofulvin
Others
Breakup by Distribution Channel:
Hospitals and Clinics
Online Stores
Retail Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc. and The OTC Lab B.V.
Report Coverage:
Report Features
Details
Base Year of the Analysis
2022
Historical Period
2017-2022
Forecast Period
2023-2028
Units
US$ Billion
Segment Coverage
Disease Type, Treatment Type, Drug Class, Distribution Channel, Region
Region Covered
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered
Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc. and The OTC Lab B.V
Customization Scope
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
10-12 Weeks
Delivery Format
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global onychomycosis treatment market was valued at US$ 3.1 Billion in 2022.
We expect the global onychomycosis treatment market to exhibit a CAGR of 5.37% during 2023-2028.
The high prevalence of onychomycosis among the masses, along with the advent of water-soluble antifungal treatment solutions, is primarily driving the global onychomycosis treatment market.
The sudden outbreak of the COVID-19 pandemic has led to the rising inclination towards e-pharmacy solutions that administer the onychomycosis treatment via providing topical nail lacquers and ointments to maintain nail hygiene.
Based on the disease type, the global onychomycosis treatment market can be categorized into distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis, candidal onychomycosis, and others. Among these, distal subungual onychomycosis holds the majority of the total market share.
Based on the treatment type, the global onychomycosis treatment market has been segmented into laser therapy, photodynamic therapy, and drug treatment. Currently, drug treatment represents the largest market share.
Based on the distribution channel, the global onychomycosis treatment market can be bifurcated into hospitals and clinics, online stores, retail pharmacies, and others. Among these, retail pharmacies account for the majority of the total market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global onychomycosis treatment market include Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc., and The OTC Lab B.V.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
This site uses cookies (including third-party cookies) to record user’s preferences which help us to enhance our services. For further information review our Privacy Policy.
This site uses cookies to improve user experience.Privacy Policy.